Information Provided By:
Fly News Breaks for June 28, 2016
RARE
Jun 28, 2016 | 06:31 EDT
BofA/Merrill initiated Ultragenyx with a Buy and $72 price target. The analyst said Ultragenyx is positioning itself for long-term growth and has 4 late-stage clinical assets to treat orphan diseases that could generate $1.2B in revenue.
News For RARE From the Last 2 Days
There are no results for your query RARE